PepGen (NASDAQ:PEPG) Stock Crosses Above 200 Day Moving Average on Disappointing Earnings

PepGen, Inc. (NASDAQ:PEPG)’s stock price passed above its 200-day moving average during trading on Tuesday following a stronger than expected earnings report. The stock has a 200-day moving average of $2.98 and traded as high as $6.45. PepGen shares last traded at $4.61, with a volume of 105,680,478 shares.

The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.01).

PepGen News Roundup

Here are the key news stories impacting PepGen this week:

• Positive Sentiment: PepGen reported positive Phase 2 FREEDOM2-DM1 results at the 10 mg/kg dose, including the highest reported splicing correction and improvements across multiple functional measures. The data drove the sharp rally and raised expectations for the treatment’s potential. Article: PepGen Announces Positive Phase 2 FREEDOM2-DM1 Results
• Positive Sentiment: Bank of America upgraded PEPG from “underperform” to “neutral” and set a $6 price target, adding support to sentiment after the trial news. Article: Bank of America Ratings
• Neutral Sentiment: The company proposed a $125 million public offering of common stock. The financing could provide funds for development, but issuing shares may dilute existing shareholders. Article: Proposed $125 Million Offering
• Negative Sentiment: PepGen reported a third-quarter loss of $0.28 per share, slightly wider than analysts’ $0.27 estimate. This was a modest miss, though the trial results appear to have been the stronger near-term market catalyst. Article: PepGen Third-Quarter 2026 Results

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on PEPG. Weiss Ratings upgraded PepGen from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, September 22nd. Bank of America upgraded PepGen from an “underperform” rating to a “neutral” rating and set a $6.00 price objective for the company in a research note on Tuesday. Wall Street Zen raised PepGen from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, HC Wainwright reaffirmed a “buy” rating on shares of PepGen in a research report on Wednesday, September 9th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $10.50.

Institutional Trading of PepGen

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PEPG. Rangeley Capital LLC increased its position in shares of PepGen by 88.1% in the 1st quarter. Rangeley Capital LLC now owns 68,096 shares of the company’s stock valued at $121,000 after purchasing an additional 31,896 shares during the last quarter. Group One Trading LLC acquired a new stake in shares of PepGen in the 1st quarter valued at $77,000. Seven Fleet Capital Management LP purchased a new stake in shares of PepGen during the 1st quarter worth $105,000. Dimensional Fund Advisors LP lifted its position in shares of PepGen by 60.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 216,824 shares of the company’s stock worth $394,000 after purchasing an additional 81,608 shares during the last quarter. Finally, Persistent Asset Partners Ltd purchased a new stake in shares of PepGen during the 2nd quarter worth $171,000. Institutional investors and hedge funds own 58.01% of the company’s stock.

PepGen Price Performance

The business’s 50 day moving average is $2.69 and its 200 day moving average is $2.98. The stock has a market cap of $319.29 million, a price-to-earnings ratio of -3.52 and a beta of 2.02.

PepGen Company Profile

PepGen Inc. is a clinical-stage biotechnology company developing genetic medicines for serious neuromuscular diseases. The company’s technology is designed to improve the delivery of oligonucleotide therapeutics into skeletal and cardiac muscle, with the goal of addressing diseases caused by genetic mutations or abnormal RNA processing. PepGen’s platform, known as Enhanced Delivery Oligonucleotides (EDO), combines therapeutic oligonucleotides with proprietary peptides intended to facilitate their distribution into muscle tissue.